Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin for Renal Protection in Patients Receiving Polymyxin B
NCT03725267Phase 2Terminated
- Sponsor
- Hospital de Clínicas de Porto Alegre
- Start
- Oct 2018
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute kidney injury (AKI) comparing Melatonin with Placebo (2 arms). Primary endpoint: Acute Kidney Injury according to RIFLE criteria at 14 days. Started Oct 2018; status: terminated.
02
Drugs
melatonin
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT03725267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03725267.